Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for NSTM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -0.0336M
March 31, 2026 -0.1387M
December 31, 2025 -0.0262M
September 30, 2025 -0.031M
June 30, 2025 -0.0668M
March 31, 2025 -0.0437M
December 31, 2024 -0.0392M
September 30, 2024 -0.0626M
June 30, 2024 -0.0973M
March 31, 2024 -0.0729M
December 31, 2023 -0.0789M
September 30, 2023 -0.0724M
June 30, 2023 -0.1692M
March 31, 2023 -0.0278M
December 31, 2022 -0.1255M
September 30, 2022
June 30, 2022
March 31, 2022
December 31, 2021
September 30, 2021
June 30, 2021
March 31, 2021
December 31, 2020
September 30, 2020
June 30, 2020
Date Value
March 31, 2020
December 31, 2019
September 30, 2019
June 30, 2019
March 31, 2019
December 31, 2018
September 30, 2018
June 30, 2018
March 31, 2018
December 31, 2017
September 30, 2017
June 30, 2017
March 31, 2017
December 31, 2016
September 30, 2016
June 30, 2016
March 31, 2016
December 31, 2015
September 30, 2015
June 30, 2015
March 31, 2015
December 31, 2014
September 30, 2014
June 30, 2014
March 31, 2014

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Brainstorm Cell Therapeutics, Inc. -0.895M
Summit Therapeutics, Inc. -140.55M
Kezar Life Sciences, Inc. -7.445M
Protara Therapeutics, Inc. -15.39M
Clene, Inc. -2.578M

Cash from Operations (Quarterly) Related Metrics